Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $1.00 (169.47% upside)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Noble FinancialReiterated RatingBuy$1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016FBR & CoReiterated RatingOutperform$1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Roth CapitalReiterated RatingHold$0.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015MLV & Co.Reiterated RatingBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
9/7/2016        
7/14/2016Q416($0.03)($0.05)$18.78 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q316($0.07)($0.08)$7.96 million$6.71 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/10/2015Q216($0.09)($0.07)$9.52 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/9/2015Q116($0.08)($0.08)$9.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/14/2015Q315($0.08)($0.07)$6.42 million$9.31 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q215($0.08)($0.08)$4.20 million$5.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/10/2014Q115($0.07)($0.07)$5.82 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/9/2014Q1($0.06)($0.08)$5.76 million$5.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/14/2014Q414($0.07)($0.06)$4.75 million$6.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2014Q314($0.06)($0.06)$5.09 million$3.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/10/2013Q2($0.05)($0.05)$5.74 million$7.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/9/2013Q1 2014($0.05)($0.05)$4.75 million$4.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/11/2013Q4 2013($0.06)($0.06)$3.57 million$4.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q3 2013($0.07)($0.04)$3.90 million$7.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/10/2012-0.08($0.09)($0.08)$4.03 million$4.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/10/2012Q113($0.11)($0.07)$3.97 million$4.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/16/2012($0.13)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2012($0.13)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/12/2011($0.13)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/9/2011($0.14)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.05)($0.05)($0.05)
Q4 20161($0.05)($0.05)($0.05)
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateHeadline
07/29/16 12:47 PMETF’s with exposure to Peregrine Pharmaceuticals, Inc. : July 29, 2016 -
07/25/16 06:04 PMPeregrine Pharmaceuticals (PPHM) Shares are Down -1.09% - Trade Calls
07/22/16 08:51 AMEquity Roundup: Stock Performance Focus on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Press Telegraph
07/22/16 08:24 AMPeregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: 2016 By the Numbers : July 22, 2016 -
07/20/16 12:04 PMPEREGRINE PHARMACEUTICALS INC Financials -
07/20/16 08:44 AMOverview of Analysts Suggestions: CytRx Corporation (NASDAQ:CYTR) , Peregrine Pharmaceuticals Inc. (NASDAQ ... - Street Updates
07/19/16 05:00 AMIs $1.5 Price Target Attainable For Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)? - Investor Newswire
07/19/16 05:00 AMTime To Put On The Watch List? - Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), EPIRUS Biopharmaceuticals, Inc ... - The Voice Registrar
07/18/16 01:12 PMETF’s with exposure to Peregrine Pharmaceuticals, Inc. : July 18, 2016 -
07/18/16 11:22 AMAnalyst Recommended Stock: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - News Oracle
07/15/16 12:27 PMEdited Transcript of PPHM earnings conference call or presentation 14-Jul-16 8:30pm GMT -
07/15/16 11:03 AMAnalyst Rating Fluctuations to Observe: Express Scripts Holding Company (NASDAQ:ESRX) , Peregrine ... - Street Updates
07/15/16 11:03 AMAnalyst Target and Average Rating Watch: Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Press Telegraph
07/15/16 11:03 AMPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 11:03 AMMix Wondering Stocks- Tesla Motors (NASDAQ:TSLA), Peregrine Pharmaceuticals (NASDAQ:PPHM), Amazon.com ... - Seneca Globe
07/15/16 11:03 AMFrontline Trades in Focus- Peregrine Pharmaceuticals (NASDAQ:PPHM), Inovio Pharmaceuticals (NASDAQ:INO ... - Seneca Globe
07/15/16 11:03 AMPeregrine Pharmaceuticals Inc. (PPHM) Drops 5.58% on July 13 - Equities.com
07/15/16 11:03 AMPeregrine Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/15/16 11:03 AMPeregrine Pharmaceuticals Inc. (PPHM) Jumps 11.57% on July 14 - Equities.com
07/14/16 03:48 PMPeregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments - [at noodls] - July 14, 2016 -- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 -- -- Growing Biomanufacturing Demand Prompts Plans ...
07/14/16 03:39 PMPEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo -
07/14/16 07:38 AMPeregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center - [at noodls] - July 14, 2016 --New Technology Efficiently Builds on the Company's Existing Phosphatidylserine (PS) Targeting Platform and Assay Development Capabilities-- --Stand Alone Program That Offers Significant ...
07/13/16 08:50 AMPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 08:50 AMStrong Sell Calls For Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) At 0 - Investor Newswire
07/13/16 08:50 AMDo Institutional Investors Love Peregrine Pharmaceuticals Inc (NASDAQ:PPHM)? - Press Telegraph
07/08/16 05:56 PMCompany Stock Focus for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM): Which Way Will Shares Head? - Press Telegraph
07/07/16 03:31 PMPeregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016 - [at noodls] - July 7, 2016 TUSTIN, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by delivering ...
07/06/16 10:34 AMPeregrine Pharmaceuticals Inc. (PPHM) Broker Price Targets For The Coming Week - Fiscal Standard
07/06/16 10:34 AMPeregrine Pharmaceuticals Inc. (PPHM) Jumps 9.61% on July 04 - Equities.com
07/05/16 05:39 PMShare Performance Recap for: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Press Telegraph
06/28/16 05:50 PMPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Company Rating and Target Watch - Telanagana Press
06/27/16 05:54 PMNotable Stock's Buzzers: Whiting Petroleum Corp (NYSE:WLL), Peregrine Pharmaceuticals (NASDAQ:PPHM) - NYSE Journal (press release)
06/27/16 05:54 PMStrong Sell Calls Recommendations For Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) At 0 - Investor Newswire
06/27/16 10:03 AMShare Update and Earnings Review for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Press Telegraph
06/27/16 10:03 AMQUALCOMM, Inc. (NASDAQ:QCOM) & Peregrine Pharmaceuticals (NASDAQ:PPHM) News Recap - Wall Street 24
06/27/16 10:03 AMHC Stocks News: Peregrine Pharmaceuticals (NASDAQ:PPHM), Boston Scientific Corporation (NYSE:BSX) - share market updates (press release)
06/25/16 05:20 PMCovering the Bases on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM): Where is the Stock Going? - Press Telegraph
06/25/16 05:20 PMPeregrine Pharmaceuticals Inc. (PPHM) Current Analyst Ratings - Fiscal Standard
06/25/16 05:20 PMPrice Target Update on Peregrine Pharmaceuticals (NASDAQ:PPHM) - Trade Calls
06/20/16 05:41 PMStrong Buy Calls Count For Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) At 2 - Investor Newswire
06/20/16 07:29 AMThis Weeks Broker Views For Peregrine Pharmaceuticals Inc. (PPHM) - Fiscal Standard
06/15/16 10:30 AMMost Active Stocks Update: WestRock Company (NYSE:WRK), Peregrine Pharmaceuticals (NASDAQ:PPHM) - Beacon Chronicle
06/15/16 10:30 AMHC Stocks Growth: Peregrine Pharmaceuticals (NASDAQ:PPHM), Zimmer Biomet Holdings Inc (NYSE:ZBH) - share market updates (press release)
06/15/16 10:30 AMFloating Price Update: Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) , PharmAthene, Inc (NYSEMKT:PIP) - Street Updates
06/11/16 08:46 AMEarnings Overview: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), Xenoport, Inc. (NASDAQ:XNPT) - Beacon Chronicle
06/11/16 08:46 AMPeregrine Pharmaceuticals Inc. (PPHM) Drops 7.39% on June 09 - Equities.com
06/10/16 08:56 AMMost Recent Update on Price Moves: Catalent, Inc. (NYSE:CTLT) , Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Street Updates
06/06/16 05:51 PMPeregrine's Phase III Failure Creates Opportunity Revisit - Seeking Alpha
06/06/16 09:36 AMHC Stocks Zone: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Peregrine Pharmaceuticals (NASDAQ:PPHM) - share market updates (press release)
06/06/16 09:36 AMPeregrine Pharmaceuticals (NASDAQ:PPHM) Restructures Its Leadership - Journal Transcript

Social

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Company's therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PPHM
  • CUSIP:
Key Metrics:
  • Previous Close: $0.38
  • 50 Day Moving Average: $0.3949
  • 200 Day Moving Average: $0.5263
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $89.60M
  • Beta: 1.29
  • Current Year EPS Consensus Estimate: $-0.15 EPS
  • Next Year EPS Consensus Estimate: $-0.11 EPS
Additional Links:
Peregrine Pharmaceuticals (NASDAQ:PPHM) Chart for Saturday, July, 30, 2016